WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 13'8501 Infant (under 12 months) mortality rate: 52
GDP / capita (US$): 23'4871 Child (under 5 years) mortality rate: 62

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 3'028  3'044  3'068  3'102  3'143  3'498  3'697  3'432 
Births 34  34  34  33  33  33  55  53 
Surviving infants 34  34  33  33  33  33  54  52 
Pop. less than 5 years 167  164  158  155  151  185  289  258 
Pop. less than 15 years 460  463  467  477  489  698  835  800 
Female 15-49 years 774  785  798  810  824  886  924  887 

Number of reported case

(Click for retrospective incidence data for Lithuania)
Diphtheria
Japanese encephalitis
Measles 19 
Mumps 62  64  87  74  82  4'377 
Pertussis 154  30  19  233  51  91 
Polio*
Rubella 1'304 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Lithuania)
Vaccine year result method % card seen                                                
BCG          98  98  99  99  99  99 
DTP1          97  95  98  98  96  99 
DTP3          93  92  95  98  96  94 
HepB_BD          96  98  98  92  99 
HepB3          93  95  95  95  96  99 
Hib3          93  92  95  98  96 
JapEnc         
MCV          93  94  96  96  97  97 
MCV2          93  94  95  94  96  97 
PCV1         
PCV3         
Pol3          93  92  95  98  96  92 
Rota1         
Rota_last         
Rubella1          93  94  96  96 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Lithuania)
BCG 98  98  99  99  99  99 
DTP1 97  95  98  98  96  99 
DTP3 93  92  95  98  96  94 
HepB3 93  95  94  95  96  98 
Hib3 93  92  95  98  96 
MCV 93  94  96  96  97  97 
PCV3
Pol3 93  92  95  98  96  92 
Rota_last

Number of districts in the country 52  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 83
From 80 to 89% 17
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 3 days; Yes
DTaPHibIPV 2, 4, 6, 18 months; Yes
DTaPIPV 6-7 years; Yes
HepB birth; 1, 6 months; Yes
MMR 15-16 months; 6-7 years; Yes
Td 15-16 years; Yes

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2009-2013  2009-2013  2009-2013  2009-2013  2006-2008  2006-2008  2006-2008 
Nº of districts with microplans that include activities to raise immunization coverage number 52  52  52  52  52  52  52 

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR Yes  Yes  Yes         

System performance

Total number of districts in country number 52  52  52  52  52  52  52 
Nº districts with DTP3 coverage >=80% number 52  51  52  52  51  52  52 
% of districts with DTP3 coverage >=80% From 0 to 100% 100  98  100  100  98  100  100 
Nº districts with measles (MCV1) coverage >=95% number 22  28  37  45  45     
% of districts with MCV1 coverage >=95% From 0 to 100% 42  54  71  87  87     

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND No  No  No         

Finance

Percentage of routine vaccines funded by Government From 0 to 100%   100  100  100  100  100  100 

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.